HISTOLOGICAL REGRESSION OF BREAST-CANCER AFTER PRIMARY (NEOADJUVANT) CHEMOTHERAPY

被引:135
|
作者
SINN, HP [1 ]
SCHMID, H [1 ]
JUNKERMANN, H [1 ]
HUOBER, J [1 ]
LEPPIEN, G [1 ]
KAUFMANN, M [1 ]
BASTERT, G [1 ]
OTTO, HF [1 ]
机构
[1] UNIV HEIDELBERG, INST PATHOL, W-6900 HEIDELBERG, GERMANY
关键词
D O I
10.1055/s-2007-1022338
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Primary (neoadjuvant) chemotherapy of locally advanced breast carcinomas is performed to locally reduce the tumour mass and to improve the operability. Recently, the indication for primary chemotherapy has. been extended for preoperative treatment in breast conserving surgery. In an ongoing clinical trial we examined the resection specimens of 51 mammary carcinomas after primary chemotherapy. These patients had received a neoadjuvant therapy with epirubicine/cyclophosphamide for size reduction of large (> 3 cm) but operable tumours (pretreatment median tumour size 4.5 cm by mammography). The tumour response was evaluated pathologically and copared with the clinical tumour regression that was observed in over two-thirds of all cases. We classified the regressive changes using a semiquantitative scoring system from 0 to 4 (0 = no effect, 1 = resorption and tumour sclerosis, 2 = minimal residual invasive tumour [< 0.5 cm], 3 = residual noninvasive tumour only, 4 = no tumour detectable). The aim of this study was to evaluate the improvement of operability objectively and to correlate the histology of the primary tumour with the response to treatment. With invasive lobular carcinomas, the tumour size after therapy was reduced less than average and irrespective of the amount of histological tumour cell reduction, largely due to the stromal content of these neoplasms. Invasive ductal carcinomas with extensive or predominant intraductal component also underwent only a slight decrease in tumour size; this was because of the lack of tumour response with the intraductal component. Well differentiated tubular carcinomas were particularly resistant to primary chemotherapy. We conclude that the response of mammary carcinomas to primary chemotherapy can at least partially be explained by the tumour differentiation and is therefore to some extent predictable with careful evaluation of the pretreatment punch biopsy. The semiquantitative histological evaluation score suggested in this article permits the classification of the treatment effects and is therefore useful for further therapy planning.
引用
收藏
页码:552 / 558
页数:7
相关论文
共 50 条
  • [21] Neoadjuvant chemotherapy for primary operable breast cancer
    Halberg, Anne Krag
    Gravesen, Charlotte Dahl
    Cold, Soren
    Jensen, Jeanette Dupont
    DANISH MEDICAL JOURNAL, 2020, 67 (12):
  • [22] SURGICAL AND HISTOLOGICAL-EVALUATION OF LOCOREGIONAL RESPONSE AFTER INTENSIVE PRIMARY CHEMOTHERAPY IN OPERABLE NON INFLAMMATORY BREAST-CANCER
    DESPAX, R
    MISSET, JL
    MUSSET, M
    GOLDSCHMIDT, E
    ECSTEIN, E
    REGENSBERG, C
    HERMOUET, M
    DHUBERT, E
    MATHE, G
    BREAST CANCER RESEARCH AND TREATMENT, 1987, 10 (01) : 108 - 108
  • [23] PRIMARY CHEMOTHERAPY FOR EARLY AND ADVANCED BREAST-CANCER
    HORTOBAGYI, GN
    BUZDAR, AU
    STROM, EA
    AMES, FC
    SINGLETARY, SE
    CANCER LETTERS, 1995, 90 (01) : 103 - 109
  • [24] THE ROLE OF CHEMOTHERAPY IN THE MANAGEMENT OF PRIMARY BREAST-CANCER
    DORR, FA
    FRIEDMAN, MA
    CA-A CANCER JOURNAL FOR CLINICIANS, 1991, 41 (04) : 231 - 241
  • [25] ADJUVANT CHEMOTHERAPY IN PRIMARY TREATMENT OF BREAST-CANCER
    BRACHETTI, AKJ
    SCHONDORF, N
    LIMBURG, H
    ARCHIV FUR GYNAKOLOGIE, 1977, 224 (1-4): : 362 - 363
  • [26] TREATMENT OF PRIMARY BREAST-CANCER WITH CHEMOTHERAPY AND TAMOXIFEN
    FISHER, B
    REDMOND, C
    BROWN, A
    WOLMARK, N
    WITTLIFF, J
    FISHER, ER
    PLOTKIN, D
    BOWMAN, D
    SACHS, S
    WOLTER, J
    FRELICK, R
    DESSER, R
    LICALZI, N
    GEGGIE, P
    CAMPBELL, T
    ELIAS, EG
    PRAGER, D
    KOONTZ, P
    VOLK, H
    DIMITROV, N
    GARDNER, B
    LERNER, H
    SHIBATA, H
    NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (01): : 1 - 6
  • [27] PRIMARY CHEMOTHERAPY IN SURGICALLY RESECTABLE BREAST-CANCER
    BONADONNA, G
    VALAGUSSA, P
    ZUCALI, R
    SALVADORI, B
    CA-A CANCER JOURNAL FOR CLINICIANS, 1995, 45 (04) : 227 - 243
  • [28] Prognostic value of subtype changes after neoadjuvant chemotherapy in primary breast cancer
    Matsumoto, Akiko
    Umemoto, Yasuko
    Yoshikawa, Mio
    Jinno, Hiromitsu
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] ADJUVANT CHEMOTHERAPY IN PRIMARY MANAGEMENT OF BREAST-CANCER
    FISHER, B
    MEDICAL CLINICS OF NORTH AMERICA, 1977, 61 (05) : 953 - 965
  • [30] Primary breast cancer: Mammographic changes after neoadjuvant chemotherapy, with pathologic correlation
    Vinnicombe, SJ
    MacVicar, AD
    Guy, RL
    Sloane, JP
    Powles, TJ
    Knee, G
    Husband, JE
    RADIOLOGY, 1996, 198 (02) : 333 - 340